Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cance

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

More... (http://www.news-medical.net/news/20100915/Provectus-completes-enrollment-in-first-cohort-of-PV-10-Phase-1-trial-for-liver-cancer.aspx)